Demographic and Clinical Presentation
AP is an acute inflammatory process of the pancreas that may involve the peripancreatic tissue and even remote organs. In the United States, about 75% to 80% cases of AP are attributed to alcohol abuse or gallstones (3
). Other factors associated with AP include medications, trauma, infections, and metabolic causes (6
). Biliary pancreatitis AP is more common in female patients, and alcoholic AP is more common in male patients (7
). Clinical presentation typically consists of severe upper abdominal pain, nausea, and vomiting. Laboratory testing reveals elevated lipase and amylase in the bloodstream.
About 75% of cases of AP in patients admitted to hospitals are mild (edematous and interstitial pancreatitis) and follow a benign, self-limited course, with discharge home by day 4 (8
). The remaining 25% cases, called severe AP (SAP), progress with the development of a profound systemic inflammatory response (SIRS), commonly associated with pancreatic gland necrosis, acute peripancreatic fluid collections, and multiorgan failure syndrome (MOFS). All the mortality (≤50%) from the condition is associated with these complications. The inflamed and swollen pancreatic gland may itself or by development of acute fluid collections compress the stomach and duodenum. The result is obstruction to the outflow from the stomach, and patients present clinically with nausea and vomiting. The SIRS is usually associated with ileus and increased mucosal permeability. These critically ill patients often spend weeks in intensive care units (ICUs) and frequently need surgery for pancreatic necrosis and infections. However, early surgery is associated with elevated mortality rates because it is extremely difficult, and every effort should be made to manage patients conservatively for more than 4 weeks with enteral nutrition (EN) until the area of pancreatic necrosis or fluid collection becomes walled off, thus allowing a more definitive approach.
Predicting Severity of Pancreatitis and Nutritional Implications
Some patients with SAP present with MOFS and profound SIRS at the outset. Others present with mild AP and then go on to exhibit features of SAP over the next few days. Predicting which of these patients will develop a severe course should help determine the urgency for intervention with specialized nutritional support. Although clinical judgment remains the easiest and most commonly used tool, it often underpredicts the severity of pancreatitis (24
). Among the laboratory studies, lipase and amylase are most widely used. Although elevated amylase and lipase are used to diagnose AP, there is no correlation between the severity of disease and elevation of these enzymes. Daily monitoring of amylase and lipase does not help in determining the prognosis or the course of the disease (25
Various scoring systems (e.g., Balthazar Score, Acute Physiology and Chronic Health Evaluation [APACHE II] score, Ranson score [Tables 81.1
and Table 81.2
]) have been employed over the years to predict severity of pancreatitis (26
). Some scoring tests can be performed on the day of admission, and some need 48 to 72 hours to complete. None of these scoring systems is accurate consistently, but these systems are somewhat better than clinical judgment (32
). This situation has led to the search for a simpler measurement.
Elevated serum creatinine concentration (>1.8 g/dL) was suggested by Muddana et al (33
) to be highly predictive of development of pancreatic necrosis, but a subsequent study by Lankish et al (34
) did not find similar association. Wu et al (35
) found the admission hematocrit (e.g., hematocrit >44 during the first 48 hours) and blood urea nitrogen (BUN) levels to be predictive of progression to severe complicated disease. Other laboratory blood tests, such as C-reactive protein (CRP), polymorphonuclear elastase, human pancreas-specific protein/procarboxypeptidase B, α2
-macroglobulin, and serum macrophage migration inhibitory factor, have been researched as markers for development of necrosis, but only CRP is clinically available at present.
TABLE 81.1 RANSON SCORE (INCLUDES EQUALLY [1 POINT] WEIGHTED VARIABLES)a
White blood cell count
>200 mg/dL (11.1 mmol/L)
Serum lactate dehydrogenase
Serum aspartate aminotransferase (AST)
Fall by ≥10%
Blood urea nitrogen
Increase by ≥5 mg/dL (1.8 mmol/L) despite fluids
<8 mg/dL (2 mmol/L)
<60 mm Hg
PO2, partial oxygen pressure.
aSome variables are assessed at presentation and others at 48 hours. Mortality is 0% to 3% with a Ranson score of less than 3, 11% to 15% a with score of 3 or more, and 40% with a score higher than 6, respectively (28).
TABLE 81.2 COMPUTED TOMOGRAPHY SEVERITY SCORE (BALTHAZAR SCORE)a
CT GRADE POINTS
Normal CT findings
Focal or diffuse enlargement of the pancreas
Pancreatic gland abnormalities and peripancreatic inflammation
Fluid collection in a single location or phlegmon
Two or more fluid collections and/or gas bubbles in or adjacent to pancreas
CT, computed tomography.
aScore is based on the degree of necrosis, inflammation, and the presence of fluid collections. In a study involving 268 patients with acute pancreatitis, patients with a score higher than 5 were 8 times more likely to die, 17 times more likely to have a prolonged hospital course, and 10 times more likely to undergo pancreatic necrosis resection than were patients with scores lower than 5 (102).
Among the imaging studies, bolus-contrasted (pancreatitis protocol) computed tomography (CT) of the pancreas can accurately differentiate interstitial from necrotizing pancreatitis. This imaging test, however, is not possible to obtain in patients who develop renal insufficiency as a complication of pancreatitis. Studies have shown that the persistence of the SIRS (with two or more of the following features: temperature >38°C or <36°C; heart rate >90 beats/minute; respiratory rate >20 breaths/minute; (4
) white blood cell count <4000 cells/mm3
or > 12,000/mm3
; or partial pressure of carbon dioxide <32 mm Hg) or organ failure after initial resuscitation is the strongest predictor of mortality (29
Pancreatic rest, as mentioned earlier, is a critical step in the initial management of all patients with AP. The need for nutritional therapy in these patients is determined by the severity of their disease.
Mild Acute Pancreatitis
In the mild form of AP, management is mainly supportive. Management strategy includes pain control, aggressive hydration with intravenous fluids, and nothing by mouth
for pancreatic rest for 48 hours. In most cases, the pain improves, nausea and vomiting resolve, serum lipase and amylase levels drop, the patient feels better, and oral intake can be retested. Traditionally, patients have been started on a clear liquid diet and then advanced to a low-fat soft diet. More recent randomized controlled trials (RCTs) have, however, reported that starting these patients on a low-fat soft diet is as safe as a clear liquid diet, with varying effect on length of hospital stay (36
). These findings suggest that after 2 to 3 days of pancreatic rest, patients can be tried on a low-fat soft diet with close monitoring for abdominal pain, nausea, vomiting, or any other complication. Once patients exhibit tolerance to this diet, they can be advanced to a regular diet over next 3 to 4 days.
Severe Acute Pancreatitis
As discussed earlier, patients with SAP represent a very sick group of patients who often go on to develop complications such as acute fluid collections, pseudocyst collections, pancreatic necrosis, and infection of fluid collection or MOSF. Mortality rates vary between 5% and 50%, depending on access to modern ICU management. Aggressive management in the ICU, especially aggressive hydration with several liters intravenous fluids to correct hypotension and maintain urine output, is crucial in initial management to prevent progression to organ failure. Patients commonly have nausea and vomiting, and eating exacerbates the pain. Consequently, they can be effective fed only by the intravenous route or by jejunal feeding combined with gastric decompression.
Only gold members can continue reading. Log In
Full access? Get Clinical Tree